New CEO Jeffrey Kindler, who replaced Hank McKinnell in July 2006, is aggressively cutting costs - eliminating jobs, streamlining manufacturing - and using the company's $28-billion cash hoard to buy back stock.
In addition, Pfizer has more than 150 drugs in its pipeline and has won several new drug approvals from the FDA in the past few years. Among them are drugs for cancer and smoking
cessation, each of which could generate more than $1 billion in annual revenue within the next five years. Meanwhile, with a dividend yield of 4.3%, Pfizer offers a bond-like